APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs). While it is often observed together with other NNRTI resistance mutations, V179I does n...

ver descrição completa

Detalhes bibliográficos
Main Authors: Richa Dwivedi, Youya Wang, Christopher Kline, Douglas K. Fischer, Zandrea Ambrose
Formato: Artigo
Idioma:English
Publicado em: Frontiers Media S.A. 2022-07-01
Colecção:Frontiers in Virology
Assuntos:
HIV
reverse transcriptase (RT)
drug resistance
non-nucleoside RT inhibitor (NNRTI)
APOBEC3
humanized mouse model
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fviro.2022.919825/full

Internet

https://www.frontiersin.org/articles/10.3389/fviro.2022.919825/full

Registos relacionados